Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

Paclitaxel 16pembrolizumab 15Carboplatin 13Specimen Handling 9Magnetic Resonance Spectroscopy 8Biopsy 7Bevacizumab 7Fulvestrant 6olaparib 5Taxes 5Megestrol Acetate 5Doxorubicin 5Cisplatin 5trastuzumab deruxtecan 4dostarlimab 4Nivolumab 4Gemcitabine 4palbociclib 3durvalumab 3Progestins 3Oxaliplatin 3Medroxyprogesterone Acetate 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Docetaxel 3Disulfides 3ribociclib 2pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × STX-478 × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡